Shanghai Fosun Pharmaceutical (Group) Co (HK:2196) has released an update.
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. has announced that its subsidiaries have received approval from the National Medical Products Administration for Desloratadine Oral Solution, a new drug aimed at treating symptoms of chronic idiopathic urticaria and allergic rhinitis. The announcement underscores the company’s continuing advancements in pharmaceutical development and its commitment to meeting medical needs.
For further insights into HK:2196 stock, check out TipRanks’ Stock Analysis page.
